DCC 2036 - Rebastinib

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 2123

CAS [1020172-07-9]

MF C30H28FN7O3
MW 553.59

  • Purity: 99%
  • Soluble in DMSO

DCC 2036


An orally active Bcr-ABL inhibitor; being a ABL Switch-control inhibitor that potently inhibits BCR-ABL1 gatekeeper mutant T315I (IC50: 0.8 nM for native ABL1 and 4 nM in a ABL1T3151 kinase assay). DCC-2036 has efficacy in a mouse model of T315I-induced CML and against cells of patients with CML. In addition, DCC-2036 also inhibited the SRC family kinases SRC, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2, but not c-KIT (IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM, 6 nM, and 481 nM respectively)
Size Unit Price Stock
5 mg €125.00 In Stock
25 mg €405.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €180.00 In Stock
2 x 25 mg €580.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...